Close this search box.

SBRT for Central and Ultra‐Central Early‐Stage Inoperable Non‐Small Cell Lung Cancer

April 23, 2024

If you cannot access the recording on ON24, you can view the webinar here.

For patients who are medically inoperable and have central or ultra-central lung cancer (CLC/UCLC), treatment options can be limited. However, in recent years, stereotactic ablative radiotherapy (SABR) or stereotactic body radiotherapy (SBRT) has improved the clinical efficacy and survival rate of CLC/UCLC patients. Despite this progress, the appropriate radiation therapy dosage remains a topic of debate.

Over the past decade, the Tianjin Medical University Cancer Institute & Hospital has conducted extensive research into the clinical application of SBRT for CLC/UCLC patients. Their findings may provide valuable insight into managing these patients. In this upcoming webinar, Dr. Yuan will share their experience and results of SBRT for CLC/UCLC in Non-Small Cell Lung Cancer.

Presenter: Yuan Zhi Yong, M.D., Professor, Chair of Radiation Oncology Department, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

Deputy head of the Radiosurgery Group of the Chinese Society of Radiation Oncology
Member of the Expert Committee on Lung Cancer of the Chinese National Cancer Center
Member of the Expert Committee on Radiotherapy Quality Control of the National Cancer Center

Dr. Yuan has established the first CyberKnife® center in China and has treated more than 10,000 cases with the CyberKnife System, especially on early-stage lung cancer, liver cancer, pancreatic cancer, intracranial tumors as well as vertebral lesions. Dr. Yuan and his team have published more than 50 SCI papers.

Moderator: Joost J. Nuyttens, M.D., Ph.D., Radiation Oncologist, Erasmus MC Cancer Institute, Rotterdam, The Netherlands 

Dr. Nuyttens has been working in the Department of Radiation Oncology at Erasmus MC since 2001 and is currently an assistant professor in radiation oncology and director of the CyberKnife program. His focus is on thoracic and digestive cancer. He has published more than 100 publications in international journals and a number of book chapters on stereotactic radiotherapy for lung tumors. Dr. Nuyttens has used the CyberKnife System to treat early-stage NSCLC, oligometastasis, and pancreatic cancer. 

In 1996, Dr Nuyttens graduated from the Medical School at Ghent University in Belgium, where he also did his post-graduate medical speciality training in radiotherapy. He completed his education with advanced Radiation Oncology training at the Medical University of South Carolina (USA) and was a research fellow at the William Beaumont Hospital in Detroit (USA).